1-5 of 5
John N. Allan
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

An indirect comparison of acalabrutinib with and without obinutuzumab vs zanubrutinib in treatment-naive CLL

Clinical Trials & Observations
Adam S. Kittai, John N. Allan, Dan James, Helen Bridge, Miguel Miranda, Alan S. M. Yong, Fady Fam, Jack Roos, Vikram Shetty, Alan Skarbnik, Matthew S. Davids
Journal: Blood Advances
Blood Adv (2024) 8 (11): 2861–2869.
https://doi.org/10.1182/bloodadvances.2023012142
Published: 2024
Includes: Supplemental data
Journal Articles

Hypertension treatment for patients receiving ibrutinib: a multicenter retrospective study

Clinical Trials & Observations
Laura Samples, Jenna Voutsinas, Bita Fakhri, Sirin Khajavian, Stephen Spurgeon, Deborah Stephens, Alan Skarbnik, Anthony Mato, Catherine Broome, Ajay Gopal, Stephen Smith, Ryan Lynch, Magdalena Rainey, Myung Sun Kim, Odeth Barrett-Campbell, Emily Hemond, Mazie Tsang, Daniel Ermann, Nikita Malakhov, Danielle Rao, Mehrdad Shakib-Azar, Beth Morrigan, Ayushi Chauhan, Thomas Plate, Ted Gooley, Kellie Ryan, Frederick Lansigan, Brian Hill, Georgios Pongas, Sameer A. Parikh, Lindsey Roeker, John N. Allan, Richard Cheng, Chaitra Ujjani, Mazyar Shadman
Journal: Blood Advances
Blood Adv (2024) 8 (9): 2085–2093.
https://doi.org/10.1182/bloodadvances.2023011569
Published: 2024
Journal Articles

Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen

Clinical Trials & Observations
Meghan C. Thompson, Rosemary A. Harrup, Catherine C. Coombs, Lindsey E. Roeker, Jeffrey J. Pu, Michael Y. Choi, Paul M. Barr, John N. Allan, Martin Šimkovič, Lori Leslie, Joanna Rhodes, Elise A. Chong, Manali Kamdar, Alan Skarbnik, Frederick Lansigan, Brittany McCall, Khalid Saja, Martin J. S. Dyer, Harriet S. Walter, Marcus Lefebure, Maria Thadani-Mulero, Michelle Boyer, Juliana Biondo, Kavita Sail, Beenish S. Manzoor, Richard Furman, Kurt S. Bantilan, Andre Goy, Tatyana Feldman, Dominic Labella, Stephen J. Schuster, Jae Park, Lia Palomba, Andrew Zelenetz, Toby A. Eyre, Arnon P. Kater, John F. Seymour, Anthony R. Mato
Journal: Blood Advances
Blood Adv (2022) 6 (15): 4553–4557.
https://doi.org/10.1182/bloodadvances.2022007812
Published: 2022
Journal Articles

Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies

Clinical Trials & Observations
Matthew S. Davids, Owen A. O’Connor, Wojciech Jurczak, Felipe Samaniego, Timothy S. Fenske, Pier Luigi Zinzani, Manish R. Patel, Nilanjan Ghosh, Bruce D. Cheson, Enrico Derenzini, Danielle M. Brander, James A. Reeves, Wanda Knopińska-Posłuszny, John N. Allan, Tycel Phillips, Paolo F. Caimi, Ewa Lech-Maranda, John M. Burke, Richy Agajanian, Ruth Pettengell, Lori A. Leslie, Chan Y. Cheah, Gustavo Fonseca, James Essell, Julio C. Chavez, John M. Pagel, Jeff P. Sharman, Yanzhi Hsu, Hari P. Miskin, Peter Sportelli, Michael S. Weiss, Ian W. Flinn
Journal: Blood Advances
Blood Adv (2021) 5 (23): 5332–5343.
https://doi.org/10.1182/bloodadvances.2021005132
Published: 2021
Includes: Supplemental data
Journal Articles

A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL

Clinical Trials & Observations
Anthony R. Mato, Lindsey E. Roeker, Toby A. Eyre, Chadi Nabhan, Nicole Lamanna, Brian T. Hill, Danielle M. Brander, Paul M. Barr, Frederick Lansigan, Bruce D. Cheson, Arun K. Singavi, Maryam Sarraf Yazdy, Nirav N. Shah, John N. Allan, Erica B. Bhavsar, Joanna Rhodes, Kaitlin Kennard, Stephen J. Schuster, AnnaLynn M. Williams, Alan P. Skarbnik, Andre H. Goy, Julie M. Goodfriend, Colleen Dorsey, Catherine C. Coombs, Hande Tuncer, Chaitra S. Ujjani, Ryan Jacobs, Allison M. Winter, John M. Pagel, Neil Bailey, Anna Schuh, Mazyar Shadman, Andrea Sitlinger, Hanna Weissbrot, Sivraj Muralikrishnan, Andrew Zelenetz, Amy A. Kirkwood, Christopher P. Fox
Journal: Blood Advances
Blood Adv (2019) 3 (10): 1568–1573.
https://doi.org/10.1182/bloodadvances.2019000180
Published: 2019